Andrew C. Ip MD MSc
Hematologic Oncology
Division of Lymphoma Outcomes and Value Based Care Division
Join to View Full Profile
92 2nd StreetHackensack, NJ 07601
Dr. Ip is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- As chief of the Outcomes and Value Care Division and a member of the Division of Lymphoma at John Theurer Cancer Center, I lead the center’s outcomes and values care research effort. My focus is on reviewing data about cancer patients across the Hackensack Meridian Health system to understand how to achieve the best patient outcomes as well as value from their outcome, whether it be cost or improved quality of life.
Education & Training
Emory University, Laney Graduate SchoolMSc, Clinical research, 2017 - 2019
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2016 - 2019- Emory University School of MedicineResidency, Internal Medicine, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2012
Certifications & Licensure
NJ State Medical License 2019 - 2027
NY State Medical License 2024 - 2026
GA State Medical License 2014 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.Coen J Lap, James Di Palma-Grisi, Andrew Ip, Joseph L Roswarski
Hematological Oncology. 2026-07-01 - Impact of Bridging Response on Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Beatriz Wills, Sarah Samorodnitsky, Samantha Brown, Jessica R Flynn, Sean Devlin
Transplantation and Cellular Therapy. 2026-06-12 - 1 citationsCD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.Silvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, Parastoo B Dahi, Sigrun Einarsdottir
American Journal of Hematology. 2026-06-01
Journal Articles
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyNoa Biran, Andrew Ip, Ronaldo Collo Go, The Lancet Rheumatology
Authored Content
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020
Press Mentions
New Model Can Help Clinicians to Predict 40-Day Mortality Risk in Hospitalized COVID-19 PatientsAugust 2nd, 2021- Diagnosis, Clinical Characteristics, and Outcomes of COVID-19 Patients from a Large Healthcare System in Northern New JerseyFebruary 23rd, 2021
- Yale Doctor Slams Fauci for His Dismissal of Hydroxychloroquine in COVID TreatmentFebruary 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
